- Report
- January 2026
- 195 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 186 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- August 2025
- 136 Pages
Middle East
From €5211EUR$5,950USD£4,523GBP
- Book
- February 2025
North America
Candidiasis is a type of fungal infection caused by the yeast Candida. It is the most common type of fungal infection in humans, and can affect the skin, mucous membranes, and other organs. Infectious disease testing is used to diagnose candidiasis, and can involve culturing the organism, antigen detection, or molecular testing. Treatment typically involves antifungal medications, and in some cases, surgery.
The candidiasis market within the context of infectious disease testing is a growing field, with a range of products available to diagnose and treat the condition. Diagnostic tests include antigen detection, molecular testing, and culturing, while treatments include antifungal medications and, in some cases, surgery.
Companies in the candidiasis market include Abbott, Becton Dickinson, Bio-Rad, Cepheid, DiaSorin, Hologic, and Roche. Show Less Read more